Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
NCT ID: NCT04566393
Last Updated: 2026-01-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Ulixertinib is available for treatment as monotherapy or in combination with other clinically tolerable agent(s), conditionally approved by the drug manufacturer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
NCT06714617
Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
NCT05172700
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
NCT07306559
A Study of BMS-863233 in Patients With Hematologic Cancer
NCT00838890
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ulixertinib (BVD-523)
Ulixertinib (BVD-523) is an oral, first-in-class ERK1/2 inhibitor
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1\. Patient has a MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations.
1. In the opinion of the treating physician, the patient has exhausted or has inadequate response to available anti-cancer treatments.
2. In the opinion of the treating physician, the patient has adequate organ function to tolerate ulixertinib as defined in section 6.1
3. Male or female patients aged ≥ 12 years.
4. Patient must be able to swallow and retain orally administered medication.
Note: Ulixertinib is primarily absorbed in the duodenum and therefore patients with any prior stomach or duodenal resection should be evaluated with that understanding.
5. For females, evidence of post-menopausal status or negative urinary or serum pregnancy test for pre-menopausal patients.
6. Highly effective contraception for both male and female patients throughout the treatment and for at least 4 months after last treatment administration. In patients under the age of 18, who are not sexually active, abstinence is an acceptable form.
7. Toxicities related to any prior treatments are either stable, stable on supportive therapy, resolved, or in the opinion of the treating physician, clinically non-significant
8. Ability to understand a written informed consent document, and the willingness to sign it. Assent will be obtained when appropriate based on the patient's age.
Exclusion Criteria
2. Patient has received systemic therapy with an investigational agent within 5 half-lives or 14 days prior to starting ulixertinib treatment, whichever is shorter.
3. Patient has received radiotherapy within 14 days prior to the first dose of ulixertinib treatment other than for the allowable treatment of symptomatic bone metastasis.
4. A history of current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)
5. Current evidence of uncontrolled, significant intercurrent illness that would, in the treating physician's judgment, contraindicate the patient's treatment with ulixertinib due to safety concerns.
6. Patients who, in the opinion of the treating physician, have not fully recovered from recent major surgery to a sufficient extent to tolerate treatment with ulixertinib.
7. Known hypersensitivity to ulixertinib or any component in its formulation.
8. Patients taking prohibited medications as described in current Investigator's Brochure.
Note: Patients who require treatment with Drugs that are strong inhibitors or inducers of CYP1A2, CYP2D6, and CYP3A4 (see Appendix 3) were excluded from the FIH study of ulixertinib and should be discussed with xCures to review if any potential benefits outweigh the potential risks.
9. Patient is actively breastfeeding.
10. Prior stomach or duodenal resection that in the opinion of the treating physician would affect the breakdown and absorption of ulixertinib.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cancer Commons
OTHER
xCures
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clearview Cancer Institute
Huntsville, Alabama, United States
Infirmary Cancer Care
Mobile, Alabama, United States
PCR Oncology
Arroyo Grande, California, United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
xCures Inc.
San Francisco, California, United States
Providence Saint John's Health Center
Santa Monica, California, United States
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, United States
Orlando Health
Orlando, Florida, United States
Mercy Medical Center
Cedar Rapids, Iowa, United States
Unity Point Health - St. Lukes Hospital
Cedar Rapids, Iowa, United States
Our Lady of the Lake Hospital
Baton Rouge, Louisiana, United States
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, United States
Oakland Macomb Cancer Specialists
Sterling Heights, Michigan, United States
Lake Region Healthcare
Fergus Falls, Minnesota, United States
Nebraska Hematology Oncology
Lincoln, Nebraska, United States
Cancer Partners of Nebraska
Lincoln, Nebraska, United States
Hunterdon Hematology Oncology
Flemington, New Jersey, United States
Monmouth Medical Center
Long Branch, New Jersey, United States
The Minniti Center for Medical Oncology and Hematology
Mickleton, New Jersey, United States
Atlantic Health System/Overlook Medical Center
Summit, New Jersey, United States
Hirschfeld Oncology
Brooklyn, New York, United States
Stony Brook Cancer Center
Stony Brook, New York, United States
The Christ Hospital
Cincinnati, Ohio, United States
Lehigh Valley Health Network
Allentown, Pennsylvania, United States
MD Anderson
Houston, Texas, United States
UTHealth Houston
Houston, Texas, United States
UTHealth - Tyler
Tyler, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ULI-EAP-100
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.